Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.

Abstract: The present patent application relates to a pharmaceutical composition, characterized in that it comprises at least one active ingredient which can bring about a singlet oxygen-independent direct catalase inactivation and that the composition further comprises at least one active ingredient that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation.

Abstract: The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.

Abstract: A method of MR imaging and spectroscopy to reduce artifacts occurring due to the motion of an object to be represented, wherein the object position is determined quasi-continuously during the runtime of the MR acquisition, which includes one or more partial acquisitions (TA), and wherein motion correction is performed, which comprises dynamic adaptation of the frequency and phase settings of the RF system of the tomograph and of the orientation and amplitudes of the gradients during the runtime of the MR acquisition according to the current object position. The motion correction is thereby applied during a signal weighting period, during a signal read-out period, or between and/or during the two stated periods and the adaptations for motion correction are performed without interrupting or slowing the temporal progression of the MR acquisition. In this way, artifacts due to motion of the object to be represented can be further reduced.

Abstract: A method of MR imaging applies a magnetic field Bgrad1 having a spatially non-linear dependence to select a volume of at least one curved slice. The slice is described by its midsurface AM, a volume of the selected slice being made up of n? partial volumes in each of which gradients of at least one pair of remaining superimposed magnetic fields Bgradi (i>1) exhibit an angle dependence of 70° to 110° with respect to one another and with respect to the normal of the midsurface AM. At least one superimposed magnetic field of the respective pair exhibits a spatially non-linear dependence and combinations of these pairs are used for spatial encoding. In this way, curved surfaces can be mapped efficiently in high resolution and the method can be adapted to the slice shape.

Abstract: The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.

Abstract: A method for measuring the cerebral perfusion of a living organism (1) by means of magnetic resonance (=“MR”) imaging proposes acquisition of further MR signals in a slice (5) that is pervaded by an artery that supplies the blood to the brain in order to determine the temporal progression of the concentration of the contrast medium during the bolus passage in the artery. During acquisition of the further MR signals, a magnetic field gradient is applied in such a way that projection images of the slice are generated. In each time interval between the excitations of the further MR signals, at least one radio-frequency (=“RF”) pulse is irradiated that causes saturation of the nuclear spin magnetization in the slice. This enables simultaneous measurement of the contrast medium flow in the vessels supplying the brain and the brain tissue within the same sequence with an adapted dynamic range.

Abstract: A method for the diagnosis and/or therapy control of systemic sclerosis is disclosed wherein soluble CD90 is detected in body fluids. By measuring the concentration of soluble CD90 certain forms of diseases can be differentiated by applying the ex vivo method.

Abstract: The present invention is directed to a bio-functionalized stimulus-responsive dissolvable PEG-hydrogel. This inventive stimulus-responsive dissolvable PEG-hydrogel comprises a matrix of PEG-polymers, which are modified to contain at least one multifunctional fusion protein, the multifunctional fusion protein preferably comprising as components a substrate binding peptide (SBP), preferably a repetitive RGD-binding peptide and/or a ZZ-binding domain, preferably a tag for purification, and at least one N- and/or C-terminal linker. The present invention is furthermore directed to the use of such inventive stimulus-responsive dissolvable PEG-hydrogels in the treatment of lesions, in surgical dressings, for wound treating, for soft and hard tissue regeneration, for the treatment of wounds in the oral cavity, in the field of ophthalmology, in the field of periodontal defects, etc. The invention also describes a method of treatment for such diseases.

Abstract: In a control method and control unit to monitor a data acquisition of magnetic resonance image data of an imaging area located in a measurement volume of a magnetic resonance apparatus, an RF excitation pulse is radiated by an RF transmission/reception device of the magnetic resonance apparatus, raw data are acquired after a time after the radiated excitation pulse, by means of the RF transmission/reception device, and store the raw data, the raw data are transmitted to a monitoring unit and (a) through (c) are repeated while switching different gradients for spatial coding by readout of k-space corresponding to the imaging area along trajectories that are predetermined by the switched gradients, up to a termination criterion that is predetermined by the monitoring unit.

Abstract: The present application relates to an ex vivo or in vitro method to determine the presence or absence of a mutation or a variation in the NF-E2 gene in a sample from a patient suffering from a myeloid neoplasm or solid tumor whereby said method comprises: a) obtaining a nucleic acid sample from the patient, b) detecting the presence or absence of a mutation in the nucleic acid sample comprising the NF-E2 gene or a fragment thereof, characterized in that the presence of the mutation is an indication of a myeloid neoplasm or solid tumor, whereby the mutation is determined by comparing the nucleic acid sequence obtained from the sample with SEQ ID NO:1 or the complement thereof.

Abstract: The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogues.

Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.

Abstract: The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these cells. The level of ROS can be increased by increasing the level of nitric oxide through inhibition of the enzymes nitric oxide dioxygenase or arginase. According to the present invention inhibitors of the nitric oxide dioxygenase or arginase can be used for the manufacture of a medicament for the treatment of cancer. The present invention further provides a method for identifying compounds which can be used for the treatment of cancer, wherein the method allows to specifically identify compounds which induce apoptosis through the ROS signaling pathway. The present invention also provides a kit for identifying compounds which induce tumor apoptosis by inactivating a catalase on the tumor cell surface.

Abstract: A method for magnetic resonance (=MR) imaging, wherein non-linear gradient fields are applied for the purpose of spatial encoding to acquire images of an object to be imaged and wherein the magnet resonance signal radiated from the object to be imaged is sampled on grids in time, to thereby obtain sampling points, is characterized in that the object to be imaged is mapped completely in regions of stronger gradient fields by increasing the density of the sampling points in the center of k-space, and additional sampling points are specifically acquired in the outer regions of k-space according to a k-space sampling pattern depending on the desired distribution of the resolution in the measurement, wherein the MR measurement is calculated with the additional sampling points. An MR imaging method is thereby provided by means of which homogenized resolution is achieved in the MR measurements using non-linear gradient fields for spatial encoding.

Abstract: The present invention is based on the unexpected finding that, in addition to catalase, SOD is also involved in protecting tumor cells, wherein the inhibition effects of the two protective enzymes support one another in a complementary manner. The invention thus relates to pharmaceutical compositions containing at least two antibodies or the biologically active fragments thereof, wherein the one antibody is directed against the catalase and the other antibody is directed against the superoxide dismutase, as well as their use for treating a tumor disease.

Abstract: A method of MR with spatial encoding to generate an image or spectroscopic data of an object of investigation inside an MR apparatus comprises the steps of (a) selecting a volume of interest within the object of investigation, (b) applying an RF pulse to generate a transverse magnetization within the object of investigation, (c) preparing a nonlinear phase distribution within the object of investigation by application of spatially encoding magnetic fields (SEMs), the SEMs comprising of a nonlinear gradient field or a combination of linear and nonlinear gradient fields, (d) effecting primary spatial encoding through application of SEMs, and (e) recording MR signals originating from the object of investigation. Step (c) or (d) thereby comprises applying a sequence of at least two SEMs, at least one of which contains a nonlinear field gradient and at least two of the SEMs having different field geometries.

Abstract: Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.

Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.

Abstract: The present invention is directed to a biocompatible and preferably biodegradable gradient layer system comprising at least one set of layers comprising a biocompatible and preferably biodegradable cross-linked polymer and at least one biocompatible and preferably biodegradable support layer, wherein a gradient is preferably formed with respect to the mechanical and/or physical properties of one or more layers of the at least one set of layers comprising a biocompatible and biodegradable cross-linked polymer and/or the at least one biocompatible and preferably biodegradable support layer. The at least one support layer preferably comprises a biocompatible and preferably biodegradable meltable polymer and/or a biocompatible and incorporable material. This biocompatible and preferably biodegradable gradient layer system may be used as a biomaterial for regenerative medicine, particularly as a wound dressing or for tissue support.